Clinical Trial Update: Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating axitinib plus toripalimab as second-line therapy for hepatobiliary neoplasms and liver neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Neoplasms
• Hepatobiliary Neoplasm
• Liver Neoplasm

Drugs mentioned

• Axitinib (Axitinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Hepatobiliary Neoplasm, Liver Neoplasm | Phase 2 | Status: UNKNOWN